SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent showcases of its advanced agentic and voice AI solutions at a major tech conference, drawing significant community discussion around new partnerships in automotive and robotics. Investors are also actively debating the company's unique technology, which emphasizes client data privacy, and its substantial short interest.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics ($ATRA) is experiencing a significant downturn and intense community discussion after receiving a Complete Response Letter (CRL) from the FDA for its EBVALLO BLA, citing issues solely related to a third-party manufacturing facility rather than the drug's clinical efficacy or safety. While many express frustration over the unexpected delay and potential for dilution, a substantial portion of the community views this as an "overreaction" and a strategic buying opportunity, given the drug's existing approval in Europe and the high unmet medical need. Attention is now focused on the timeline for resolving manufacturing concerns, potential resubmission, and the company's exploration of strategic alternatives, including a possible acquisition by its partner, Pierre Fabre.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending lower amid a Bank of America downgrade citing over-optimistic forward estimates and heightened competitive concerns as Amazon Pharmacy now offers Novo Nordisk's popular weight-loss pill, which is notably absent from HIMS's platform. This is fueling a heated debate, with many viewing the dip as a long-term buying opportunity given HIMS's personalized healthcare and vertical integration strategy, while others anticipate further declines due to competitive pressures and regulatory scrutiny.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, primarily driven by community discussions around the potential for its LitVM and BTC_OS developments to enhance utility through programmable money and cross-chain interoperability. This is further amplified by speculation on tightening on-exchange liquidity and growing institutional interest, though a significant portion of the community remains skeptical, highlighting historical underperformance and questioning its long-term demand.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum driven by its announcement of a record total contract value exceeding a billion and a major new collaboration in genomic testing with Northwestern Medicine. The community is actively discussing the company's AI-driven growth, strategic partnerships, and Cathie Wood's recent share acquisitions, leading to speculation about further gains in the precision medicine sector.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is highly discussed following new AI partnerships with Google, which integrate Gemini for enhanced shopping experiences and expand drone delivery services. The community is actively buzzing about this strategic pivot, viewing WMT increasingly as a tech-enabled retailer ahead of its anticipated Nasdaq-100 inclusion. This narrative emphasizes Walmart's innovation and evolving market position, sparking conversations about its "growth tech stock" valuation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending following strong preliminary financial results that anticipate beating revenue guidance and an expanded partnership with Bio-Rad Laboratories to develop high-complexity cancer diagnostic assays. This positive news, coupled with significant insider buying, has fueled a surge in interest and bullish sentiment. However, community discussions are polarized, with some celebrating growth and strategic advancements, while others remain cautious due to a recent reverse stock split and ongoing concerns about cash burn.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is generating buzz due to a recently announced manufacturing partnership designed to boost production and margins. This operational catalyst is fueling speculation around a potential short squeeze on its low float, with the community actively debating the stock's dramatic price swings against concerns over potential dilution from a private placement.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed following recent FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema (HAE) and the early termination of the HSR waiting period for its Astria Therapeutics acquisition. Despite these positive developments and high analyst price targets, community sentiment expresses frustration over the stock's muted price action, often attributing it to significant short interest and past management. Investors are now keenly focused on the upcoming CEO transition to Charlie Gayer, hoping new leadership will unlock perceived undervaluation and better reflect the company's progress.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is experiencing significant trending activity following a strong earnings report that propelled its share price upward, fueling speculation of a short squeeze. However, this momentum has met with strong opposing views and a sharp pullback, as recent indications of disappointing holiday sales and a tempered forward outlook trigger investor apprehension regarding its sustained valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech.</li><li>The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock.</li><li>Intelligent Bio Solutions had announced a 1-for-10 reverse stock split effective Dec. 15.</li></ul>Shares of Intelligent Bio Solutions (INBS) have seen strong buying interest in recent weeks, with the stock adding more than 35% in premarket trading on Monday.&nbsp;From the close on Dec. 30, 2025, to Jan. 9, 2026, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> has surged about 337%, breaching both its 50-day moving average (50-DMA) and the longer-term 200-DMA during the rally.This stellar rally has made it a momentum favorite among retail traders, driven by a recent manufacturing partnership, fresh capital boost, and a compliance update with Nasdaq; however, concerns around dilution and its volatile ride continue to temper sentiment.&nbsp;<h2 class="st-heading-2">What Led To INBS Rally?</h2>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech to scale production of its fingerprint drug-screening reader. The deal is expected to cut annual production costs by over 40% and lift gross margins by about 20 percentage points, while expanding manufacturing capacity fourfold, Intelligent Bio Solutions said. The company said the deal positions it well for its U.S. market launch in 2026.The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock along with Series K-1 and K-2 warrants for the same number of shares at $4.35 each, raising around $10 million before fees. The warrants have an exercise price of $4.10 per share.Separately, on January 7, Intelligent Bio Solutions was notified by Nasdaq that it had regained compliance to trade on the Nasdaq Capital Market. The closing bid price of INBS stock had remained at $1.00 or higher for 14 consecutive business days, from Dec. 16, 2025, to Jan. 6, 2026. The company had announced a 1-for-10 reverse stock split effective Dec. 15.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the bullish premarket movement, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours. INBS was among the top-trending tickers on Stocktwits at the time of writing.One user thinks short interest is extremely high and predicts the stock could fall to $15. It is currently trading at $24.2.<stembedurl>https://stocktwits.com/Harsh1210/message/641505295</stembedurl>However, another user sees a setup that pits the company’s operational progress against short-term dilution fears.<stembedurl>https://stocktwits.com/Atdanaiw/message/641502687</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-gold-record-highs-analyst-michael-oliver-predicts-500-breakout/cmU9UNvR4Ec">Silver’s Next Move Could Be Explosive: Michael Oliver Sees $200–$500 Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback 

INBS shares were up more than 35% in premarket trading on Monday and were among the top trending tickers on Stocktwits.

INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying

Equity

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

INBS Stock Surges 132.4% on New Manufacturing Partnership 

Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026 Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus...

<ul class="summary-bullets"><li>Retail sentiment improved for SPY and QQQ on Stocktwits.</li><li>Traders are eyeing Tesla’s delivery data and a surge in silver prices.</li><li>Baidu drew retail attention after its chip unit filed for an IPO.</li></ul>U.S. stock futures were trading higher early Friday as markets reopened for the first full trading session of 2026. Wall Street is looking to break a three-year streak of opening-day losses. The S&amp;P 500 has had a negative close on its first trading day&nbsp;in each of the last three years (2023-2025).As of 2:50 a.m. ET on Friday, Nasdaq 100 futures were up 0.7%, S&amp;P 500 futures rose 0.4%, and the Dow futures gained 0.1%, while Russell 2000 futures rose 0.4%.On Stocktwits, the retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘bullish’ from ‘neutral’ a day ago. And sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid low message volumes.&nbsp;<h2 class="st-heading-2">Trending Stocks To Watch</h2> Baidu (BIDU): Trending following news that its chip unit filed for an IPO, sparking a renewed interest in ‘China AI’ discount plays. Tesla (TSLA): High search volume and social chatter ahead of its Q4 delivery report expected today. Meanwhile, reports suggest that China’s BYD has officially dethroned it as the global EV king for the full year 2025. NIO is trending high on Stocktwits as well.&nbsp; Watch out for&nbsp;iShares Silver Trust (SLV):&nbsp;Silver jumped 2.5% in early trading, building on its best annual performance since 1979.Stellantis (STLA): The company is resurrecting a gas-powered Ram pickup truck, the TRX, with a V-8 engine, as it faces fewer federal emissions regulations, CNBC reported.Other noteworthy tickers trending on Stocktwits at the time of writing were Intelligent Bio Solutions (INBS), BigBear.ai (BBAI), Corcept Therapeutics (CORT), and Sensei BioTherapeutics (SNSE).&nbsp;<h2 class="st-heading-2">Other Catalysts To Watch</h2>On the economic front, investors are looking ahead to the release of the Fed Balance Sheet (4:30 PM ET). Markets will be eyeing updates on ‘Quantitative Tightening’ (QT) pacing. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today

Wall Street is hoping to break a three-year streak of opening-day losses.

Top Medical Stocks To Consider - January 1st

Eli Lilly and Company, UnitedHealth Group, Intelligent Bio Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, and Corcept Therapeutics are the seven Medical stocks to watch today, according to...

Intelligent Bio Solutions Stock Surges 188% On New Manufacturing Partnership

(RTTNews) - Intelligent Bio Solutions Inc. (INBS) shares jumped 187.68%, trading at $11.80, up $7.70, after the company announced a new manufacturing partnership aimed at strengthening global...

Best Value Stocks To Consider - December 31st

Invesco QQQ, Ondas, Intelligent Bio Solutions, ProShares UltraPro Short QQQ, Rocket Lab, CoreWeave, and D-Wave Quantum are the seven Value stocks to watch today, according to MarketBeat's stock...

Intelligent Bio Stock Doubles On New Manufacturing Deal Promising Major Cost Cuts

Intelligent Bio Solutions stock rises after announcing a manufacturing partnership targeting over 40% cost savings, major margin improvement, and expanded global production capacity ahead of planned...

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

Aggressive shorting is met with calls for a massive squeeze as the stock continues to rally despite short positions and warnings of "big pain for shortiesss."

Traders are experiencing extreme price fluctuations with pre-market pumps to $40+ and quick reversals, creating both immense gains and losses.

Concerns loom about potential share dilution or upcoming offerings, with many questioning purchases at elevated prices when institutions received shares at $22.35.

The highly unpredictable price action and institutional share issuance are fueling sentiment that this is a "Russian Roulette" or "pump and dump" play.

INBS
Intelligent Bio Solutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INBS News

INBSIntelligent Bio Solutions Inc